Emergent BioSolutions (EBS) Wins Large Contract from DHHS to Treat Ebola; Will Manufacture in Baltimore

Image courtesy of Emergent BioSolutions

Biodefense company Emergent BioSolutions (NYSE: EBS) won a large Biomedical Advanced Research and Development Authority (BARDA) contract to treat Ebola Monoclona.

The contract is the company's first BARDA Task Order to create an Ebola treatment under the Center for Innovation in Advanced Development and Manufacturing (CIADM) program. BARDA is an authority under the U.S. Department of Health and Human Services.

The Gaithersburg, Md-based company which recently moved from Rockville, Md, will manufacture the Ebola Monoclonal Antibodies drug at it's Bayview Campus in the City of Baltimore. The state-of-the-art facility contains disposable manufacturing technology such as single use bioreactors that enable production of viral and non-viral products. Emergent says it can manufacture these drugs with a quick tunraound.

It's a big win for the profitable biotechnology company with the award valued at more than $19.7 million. Emergent says it will conduct process development, analytical method development, execute small-scale production runs, and perform cGMP cell banking leading to cGMP manufacture of bulk drug substance all under the two-year contract.

Article Image WideView 640x300: 

Stocks, Trading and Investing